News

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including ...
Medscape6d
Netherton Syndrome
A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
The Manila Times1d
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...
BioCryst Rises on Strong Sales of Rare-Disease Drug
In the first quarter, BioCryst swung to a profit of $32,000, or less than a penny a share from a loss of $35.4 million, or 17 cents a share, a year earlier. Revenue surged 57% to $145.5 million, ...
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year
Q1 2025 Management View CEO Jon Stonehouse highlighted the company’s strong performance, with ORLADEYO generating $134 ...
Seeking Alpha19d
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton ...